• Complete Data from Connect Biopharma's Phase 1b Study of CBP-201 Demonstrate Rapid, Early and Continuous Improvement in Patient Quality of Life and Atopic Dermatitis Symptoms

    1 month ago - By San Diego Biotechnology

    Results from study in adult patients with moderate-to-severe AD presented at EADV Congress
    SAN DIEGO and TAICANG, SUZHOU, China, Oct. 29, 2020 /PRNewswire/ - Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery......
    Read more ...